CheckMate 816研究是首个且唯一仅在术前使用免疫治疗联合化疗治疗早期NSCLC的大型Ⅲ期随机对照试验(randomized control trial,RCT),证实了仅术前三个周期的免疫联合化疗可带来病理完全缓解(pathologic complete response,pCR)率以及无事件生存率(...
尽管如此,我们需要MATTERHORN和DANTE的生存结果,然后才能确定pCR作为食管胃癌生存的预测因子的未来。 参考来源 https://dailynews.ascopubs.org/do/pathologic-complete-response-best-surrogate-endpoint-survival-esophagogastric-cancer 声明:本文仅供医疗卫生专...
尽管如此,我们需要MATTERHORN和DANTE的生存结果,然后才能确定pCR作为食管胃癌生存的预测因子的未来。 参考来源 https://dailynews.ascopubs.org/do/pathologic-complete-response-best-surrogate-endpoint-survival-esophagogastric-cancer (来源:肿瘤瞭望-消化时讯) 声明 凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、...
BACKGROUND: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes, including event-free survival (EFS) and overall s...
To determine the prognostic impact of pathologic lymph node (LN) status and investigate risk factors of recurrence in esophageal squamous cell carcinoma (ESCC) patients with pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (NCRT). ...
KEY OBJECTIVE: Since pathologic complete response (pCR) can be used in neoadjuvant trials to expedite drug development, can it replace event-free survival (EFS) and overall survival as primary end point in human epidermal growth factor receptor 2-positive breast cancer?
CONCLUSION: Although pCR may be useful for patient management, it cannot be considered as a surrogate for EFS or OS in neoadjuvant trials of HER2-positive, operable breast cancer. KEY OBJECTIVE: Since pathologic complete response (pCR) can be used in neoadjuvant trials to expedite drug development...
BACKGROUND: Pathologic complete response (pCR) is a common efficacy endpoint in neoadjuvant therapy trials for triple-negative breast cancer (TNBC). Previous studies have shown that pCR is strongly associated with improved long-term survival outcomes, including event-free survival (EFS) and overall ...
乳腺癌新辅助化疗病理完全缓解前哨淋巴结活检目的新辅助化疗(neoadjuvant chemotherapy,NAC)是局部晚期乳腺癌的标准治疗方案,NAC后部分患者可达到乳腺原发灶和腋窝淋巴结病理完全缓解(pathologic complete response,pCR).现有的前瞻性和回顾性研究显示,NAC后达到乳腺原发灶和腋窝淋巴结pCR的患者可得到生存获益.通过介绍NAC后...
以达到病理完全缓解(pathologicalcompleteresponse,pCR),从而获得相 对较好的预后。但局部病理学上的完全缓解是否都能化成生存获益,以及获得 pCR的患者后续是否可以豁免辅助治疗,仍然存在争议。本文从近年来国内外开 展的新辅助治疗的临床研究结果及相关研究进展着手,探讨局部进展期胃癌新辅 ...